New strategies to identify patients harbouring antibiotic-resistant bacteria at hospital admission

Clinical Microbiology and Infection

Volumn 12, Issue 2, 2006, Pages 102-109

  Tacconelli, E ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antibiotic resistance; Healthcare associated infections; Nosocomial infections; Prevention; Review; Risk factors

Indexed keywords

ANTIBIOTIC AGENT; METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL COLONIZATION; CELLULITIS; CENTRAL VENOUS CATHETER; COAGULASE NEGATIVE STAPHYLOCOCCUS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCORING SYSTEM; SKIN ULCER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 33644981541     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01326.x     Document Type: Review

References (37)

1. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003; 290: 1868-1874.
2. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59-69.
3. CDC NNIS System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2003: Issued August 2003. Am J Infect Control 2003; 31: 481-498.
4. Huang SS, Labus BJ, Samuel MC, Wan DT, Reingold AL. Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996-1999. Emerg Infect Dis 2002; 8: 195-201.
5. D'Agata EM, Horn MA, Webb GF. The impact of persistent gastrointestinal colonization on the transmission dynamics of vancomycin-resistant enterococci. J Infect Dis 2002; 185: 766-773.
6. Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML. Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 1999; 33: 283-297.
7. Tacconelli E, D'Agata EM, Karchmer AW. Epidemiological comparison of true methicillin-resistant and methicillin-susceptible coagulase-negative staphylococcal bacteraemia at hospital admission. Clin Infect Dis 2003; 37: 644-649.
8. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: A systematic review. Clin Infect Dis 2001; 32: 1055-1061.
9. Eveillard M, Ernst C, Cuviller S et al. Prevalence of methicillin-resistant Staphylococcus aureus carriage at the time of admission in two acute geriatric wards. J Hosp Infect 2002; 50: 122-126.
10. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005; 41 (suppl 4): 269-272.
11. Charlebois ED, Bangsberg DR, Moss NJ et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Franscisco. Clin Infect Dis 2002; 34: 425-433.
12. Rubinovitch B, Pittet D. Screening for methicillin-resistant Staphylococcus aureus in the endemic hospital: What have we learned? J Hosp Infect 2001; 47: 9-18.
13. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36: 131-139.
14. Fridkin SK, Hageman JC, Morrison M et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-1444.
15. Sax H, Harbarth S, Gavazzi G et al. Prevalence and prediction of previously unknown MRSA carriage on admission to a geriatric hospital. Age Ageing 2005; 34: 456-462.
16. Tacconelli E, Venkataraman L, De Girolami PCD, Agata EM. Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: Distinguishing between community-acquired versus healthcare-associated strains. J Antimicrob Chemother 2004; 53: 474-479.
17. Graffunder EM, Venezia RA. Risk factors with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49: 99-105.
18. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med 1989; 149: 1258-1262.
19. Perl TM, Cullen JJ, Wenzel RP et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. New Engl J Med 2002; 346: 1871-1877.
20. Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003; 75: 194-198.
21. Suzuki Y, Kamigaki T, Fujino Y, Tominaga M, Ku Y, Kuroda Y. Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery. Br J Surg 2003; 90: 1072-1075.
22. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17: 811-813.
23. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: A meta-analysis. Clin Infect Dis 2003; 37: 1629-1638.
24. Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 2002; 15: 162-171.
25. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002; 51: 565-567.
26. Tsiodras S, Gold S, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-208.
27. Kim WJ, Weinstein RA, Hayden MK. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. J Infect Dis 1999; 179: 163-171.
28. Fridkin SK, Yokoe DS, Whitney CG, Onderdonk A, Hooper DC. Epidemiology of a dominant clonal strain of vancomycin-resistant Enterococcus faecium at separate hospitals in Boston, Massachusetts. J Clin Microbiol 1998; 36: 965-970.
29. Tacconelli E, de Gaetano Donati K, Citton R et al. Colonisation with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus increases the risk for multidrug-resistant Pseudomonas aeruginosa colonisation. Clin Microbiol Infect 2005; 11 (suppl 2): 601.
30. Centers for Disease Control and Prevention. Public Health Dispatch: vancomycin - resistant Staphylococcus aureus Pennsylvania 2002. MMWR 2002; 51: 902.
31. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002; 51: 565 567.
32. Tacconelli E, Karchmer AW, Yokoe D, D'Agata EM. Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule. Clin Infect Dis 2004; 39: 964-970.
33. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2002; 23: 429-435.
34. Montecalvo MA, Jarvis WR, Uman J et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999; 131: 269-272.
35. Bonten M, Hayden MK, Nathan C et al. Epidemiology of colonization of patients and environment with vancomycin-resistant enterococci. Lancet 1996; 348: 1615-1619.
36. Perencevich E, Lipsitch M, Harris AD, Weinstein MC, Fisman DN. Estimating the costs and benefits of active surveillance for vancomycin-resistant enterococcus on ICU admission [abstract 122]. In: Program and abstracts of the 11th Annual Scientific Meeting of the Society for Health Care Epidemiology of America. Toronto: Society for Health Care Epidemiology of America, 2001; http://www.shea-online.org.
37. Mayhall CG. Control of vancomycin-resistant enterococci: It is important, it is possible, and it is cost-effective. Infect Control Hosp Epidemiol 2002; 21: 420-423